{"filings":[{"id":1001796,"accession_number":"0001746473-26-000092","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2026-06-11T20:52:12+00:00","items":["5.07"],"status":"ready","headline":"Pliant Therapeutics annual meeting approves all proposals; say-on-pay passes with narrow margin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class III directors Coulie, Crowell, and Krognes with 18.8M, 18.2M, and 19.3M votes for respectively.","Advisory vote on executive compensation approved: 15.3M for, 14.6M against, 0.8M abstain; 11.9M broker non-votes.","Ratification of Deloitte as independent auditor for FY2026 passed with 41.7M for, 0.7M against, 69K abstain.","Approximately 61.9M shares outstanding; broker non-votes totaled 11.9M on director and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12967,"accession_number":"0001746473-26-000088","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2026-05-11T20:07:10+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics Q1 net loss $20M; doses first patient in Phase 1b FORTIFY trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $20.0M vs $56.2M prior year; R&D expense $13.6M (down from $43.4M) due to bexotegrast termination and reduced headcount.","Cash, equivalents and short-term investments $172.4M; expected to fund operations into H2 2028.","First patient dosed in FORTIFY Phase 1b trial of PLN-101095; interim data expected in 2027.","Updated Phase 1 data at AACR showed deepening responses: one complete response, two partial responses in checkpoint-refractory tumors.","Integrin-targeted delivery platform advancing for siRNA delivery to skeletal muscle; preclinical proof-of-concept ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95150,"accession_number":"0001746473-26-000050","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pliant Therapeutics announces retirement of three directors and repricing of underwater stock options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors David Pyott, Katharine Knobil, and Suzanne Bruhn will retire effective at the 2026 Annual Meeting; all departures are not due to any disagreements.","Board approved repricing of employee stock options (including executive officers) to $1.33 per share, effective April 17, 2026.","Repricing covers options granted on or before March 1, 2025 under the 2015, 2020, and 2022 equity plans; eligible participants must stay through a 12-18 month retention period.","Affected executive officers include CEO Bernard Coulie, CFO Keith Cummings, CHRO Lily Cheung, COO Minnie Kuo, CTO Delphine Imbert, and SVP Tim Machajewski.","Underwater options were repriced to retain talent without additional dilution or cash compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108016,"accession_number":"0001746473-26-000046","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pliant Therapeutics enters $50M at-the-market equity facility with Leerink; terminates prior Cantor agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Leerink Partners for ATM offering of common stock up to $50 million.","Terminated 2021 Sales Agreement with Cantor Fitzgerald; no penalties incurred and no shares had been sold under it.","New ATM program provides continued market-based equity financing flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108015,"accession_number":"0001746473-26-000039","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics reports Q4 2025 net loss of $23.6M; advances PLN-101095 Phase 1b after positive ICI-refractory data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PLN-101095 Phase 1: 4 responders (1 CR, 3 PR) out of 10 secondary ICI-refractory patients; IFN-γ biomarker correlated with response.","Accelerated development: Phase 1b indication expansion trial initiated for NSCLC, RCC, high TMB; first patient enrollment expected Q2 2026.","Q4 2025 net loss $23.6M vs $49.7M YoY; R&D expense fell to $15.6M from $38.8M due to BEACON-IPF discontinuation.","Cash, equivalents and short-term investments $192.4M; expected to fund operations into second half 2028.","Appointed Minnie Kuo as COO; INTEGRIS-PSC Phase 2 results published in Journal of Hepatology (Jan 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108014,"accession_number":"0001746473-26-000024","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Pliant Therapeutics extends poison pill expiration to March 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended stockholder rights agreement expiration from March 11, 2026 to March 11, 2027.","Amendment entered with Computershare Trust Company on March 3, 2026.","Company states the extension is not in response to any specific takeover offer.","Rights may still be earlier redeemed, exchanged or terminated per original terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124428,"accession_number":"0001746473-25-000182","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pliant Therapeutics promotes Minnie Kuo to COO effective December 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Minnie Kuo appointed Chief Operating Officer, effective immediately; previously served as Chief Development Officer since September 2023.","Ms. Kuo has over 20 years of multinational clinical development experience, including senior roles at Vir Biotechnology, Gilead Sciences, and Roche/Genentech.","No additional compensation provided with the COO appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124427,"accession_number":"0001746473-25-000179","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pliant Therapeutics CMO Éric Lefebvre to depart on Dec 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Éric Lefebvre's employment terminates effective Dec 15, 2025.","Lefebvre expected to assist as consultant post-Separation Date for transition support.","No immediate replacement for CMO role announced by the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124426,"accession_number":"0001746473-25-000173","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics Q3 net loss narrows to $26.3M; BEACON-IPF close out near completion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.3M vs $57.8M YoY; R&D expense fell to $17.9M from $47.8M.","Cash, equivalents and short-term investments $243.3M as of Sept 30, 2025.","Phase 1 trial of PLN-101095 completed enrollment; data expected Q4 2025.","BEACON-IPF close out activities to be completed in Q4 2025.","Voluntary prepayment of Oxford Finance LLC loan completed in October 2025."],"consensus_eps_estimate":-0.5342,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124425,"accession_number":"0001746473-25-000159","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pliant Therapeutics CBO Hans Hull resigns effective October 20, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hans Hull resigned as Chief Business Officer, effective October 20, 2025.","Resignation was not due to any disagreement on operations, policies, or practices.","No replacement has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124424,"accession_number":"0001193125-25-243619","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Pliant Therapeutics prepays $32.4M to fully terminate Oxford Finance Loan Agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Prepaid $32.4M on Oct 14, 2025, covering all principal, accrued interest, fees, and expenses under Loan Agreement with Oxford Finance LLC.","Original facility was up to $150M; Pliant had drawn only $30M before the payoff.","All obligations and covenants under the agreement were fully satisfied and the loan agreement terminated.","Loan carried floating rate of greater of 1-month SOFR +5.25% or 8.75% floor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141094,"accession_number":"0001746473-25-000149","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics discontinues bexotegrast in IPF; Q2 net loss narrows to $43.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Bexotegrast development in IPF stopped due to unfavorable risk-benefit; full BEACON-IPF data to be published.","Phase 1 trial of PLN-101095 in solid tumors ongoing; data from top two dose cohorts expected by end of 2025.","Workforce restructuring largely complete; cash, cash equivalents and short-term investments at $264.4M as of June 30.","Q2 R&D expenses fell to $32.2M from $45.6M; G&A dropped to $13.4M from $15.0M.","Net loss of $43.3M improved from $55.9M in prior-year quarter, driven by restructuring and trial discontinuation."],"consensus_eps_estimate":-0.7093,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158900,"accession_number":"0001746473-25-000105","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Stockholders approve charter amendment to limit officer liability; elect three Class II directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment limiting officer liability approved with 35.2M For, 3.8M Against, 881.7K Abstain; filed June 9, 2025.","Class II directors elected: John Curnutte (34.5M For), Katharine Knobil (26.7M For), Thomas McCourt (31.6M For).","Advisory say-on-pay passed with 30.0M For, 8.9M Against, 910.9K Abstain.","Ratification of Deloitte as auditor for FY2025 approved with 50.8M For, 506K Against, 931K Abstain.","Broker non-votes totaled 12.35M shares on all proposals except auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158899,"accession_number":"0001746473-25-000097","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics Q1 net loss $56.2M, cuts workforce 45% to extend cash runway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $56.2M in Q1 2025 vs $47.0M prior-year; R&D expenses rose to $43.4M on BEACON-IPF close-out.","Announced ~45% workforce reduction on May 1, 2025, expected to be substantially completed by Q2 2025.","Cash, cash equivalents and short-term investments totaled $307.1M as of March 31, 2025.","BEACON-IPF topline data expected in Q2 2025; close-out activities ongoing.","Interim Phase 1 data for PLN-101095 plus pembrolizumab showed three confirmed partial responses in six patients at highest dose."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158898,"accession_number":"0001193125-25-109976","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"Pliant Therapeutics to cut 45% of workforce; CLO Mike Ouimette departs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction impacts ~45% of current employees; expected to substantially complete by end of Q2 2025.","Total severance and related benefits estimated at $3.6M, primarily one-time cash termination benefits.","Mike Ouimette, Chief Legal and Compliance Officer and Corporate Secretary, terminated effective May 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177305,"accession_number":"0001193125-25-053541","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Pliant Therapeutics adopts limited-duration poison pill; rights expire March 11, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted rights agreement on March 12, 2025; dividend of one right per share to holders of record March 25, 2025.","Rights become exercisable at $12.64/right if a person acquires 10% (20% for passive investors) of stock without approval.","Upon trigger, holders (excluding acquiring person) can buy shares at 50% discount; rights expire March 11, 2026.","Existing holders above thresholds are grandfathered but cannot increase ownership without losing grandfathered status.","Board may redeem rights at $0.001 each or exchange for common stock prior to trigger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177304,"accession_number":"0001746473-25-000051","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics discontinues BEACON-IPF Phase 2b trial; reports Q4 2024 net loss of $49.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BEACON-IPF discontinued after DSMB and outside expert panel recommendation due to imbalance in IPF-related adverse events; early efficacy on FVC observed.","Q4 2024 net loss of $49.7M vs $41.1M in Q4 2023; R&D expenses increased to $38.8M from $33.2M.","Cash, cash equivalents, restricted cash and short-term investments of $357.2M as of Dec 31, 2024; sufficient for 12+ months.","Appointed Delphine Imbert, Ph.D. as Chief Technical Officer, previously at Chinook Therapeutics.","Phase 1 trial of PLN-101095 in solid tumors continues; interim data from first three dose cohorts expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177303,"accession_number":"0001193125-25-025663","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pliant assembles outside expert panel to review bexotegrast trial after DSMB pause recommendation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommended pause of enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast in IPF.","Company initiated assembly of outside expert panel (pulmonary experts and biostatisticians) to review unblinded data.","Company could not determine DSMB rationale from blinded data; panel will provide independent recommendation then join expanded DSMB.","Process expected to conclude in 2-4 weeks; company remains blinded to maintain trial's potential as registrational."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177302,"accession_number":"0001193125-25-023130","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pliant Therapeutics pauses BEACON-IPF Phase 2b trial of bexotegrast after DSMB review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntarily paused enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF).","Pause follows prespecified data review and recommendations by independent Data Safety Monitoring Board (DSMB).","Patients currently enrolled in the trial will remain and be monitored while data is reviewed; blinding maintained.","Company has informed trial investigators and is in process of informing global regulatory authorities.","No details provided on DSMB rationale; lead asset trial halt likely materially negative for PLRX stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194062,"accession_number":"0001746473-24-000169","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics Q3 net loss $57.8M; BEACON-IPF enrollment on track for Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $57.8M vs $41.5M in Q3 2023; R&D expenses rose to $47.8M on BEACON-IPF trial.","Cash and investments of $406.0M as of Sept 30, 2024; no revenue reported.","BEACON-IPF Phase 2b/3 trial enrolling well; full enrollment expected Q1 2025, data mid-2026.","Phase 1 trial of PLN-101095 in solid tumors dosing third cohort; preliminary data early 2025.","Gary Palmer appointed SVP of Medical Affairs; brings 25+ years from Bristol Myers Squibb."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210391,"accession_number":"0001746473-24-000153","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Pliant Therapeutics amends bylaws to align with Delaware law and revise stockholder proposal procedures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Board approved Third Amended and Restated Bylaws effective September 24, 2024.","Amendments align bylaws with Delaware law developments and include severability provision.","Revised procedural and disclosure requirements for stockholder director nominations and other business proposals.","Changes are ministerial and conforming; no substantive operational or financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210390,"accession_number":"0001746473-24-000143","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics Q2 net loss $55.9M; cash $438.1M; bexotegrast trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $55.9M vs $41.2M prior year; R&D expense up to $45.6M driven by BEACON-IPF trial.","Cash, equivalents & short-term investments $438.1M as of June 30, 2024.","Phase 2a PET imaging trial showed reduced total lung collagen and improved FVC in IPF patients on bexotegrast.","BEACON-IPF Phase 2b enrollment on track for Q1 2025 completion; data anticipated mid-2026.","Steve Krognes, former Denali Therapeutics CFO, appointed to Board of Directors."],"consensus_eps_estimate":-0.7093,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210389,"accession_number":"0001193125-24-178937","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pliant reports positive Phase 2a data for bexotegrast in PSC; 320 mg well tolerated up to 40 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["320 mg cohort met primary safety endpoint; no treatment-related severe or serious adverse events.","Improvement in liver stiffness by transient elastography at Week 24 vs placebo.","Statistically significant reduction in alkaline phosphatase (ALP) over 24 weeks vs placebo.","MRI showed continued improvement in hepatocyte function and bile flow from Week 12 to 24.","FDA supportive of 52-week Phase 2b trial with non-invasive endpoints; program path being evaluated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228714,"accession_number":"0001746473-24-000084","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pliant Therapeutics say-on-pay vote fails; Krognes appointed to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding say-on-pay vote failed: 23,479,353 for, 28,329,655 against, 10,277 abstain.","Steve Krognes appointed as Class III director and Audit Committee chair; receives option for 53,528 shares vesting over 3 years.","Board size increased from 10 to 11 members to accommodate Krognes.","Deloitte & Touche LLP ratified as auditor for FY2024: 56,628,368 for, 10,853 against, 62,998 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228713,"accession_number":"0001193125-24-137731","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pliant Therapeutics: Phase 2a trial of bexotegrast shows reduced lung collagen and improved lung function in IPF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bexotegrast 160 mg reduced total lung collagen on PET imaging vs. increased collagen on placebo over 12 weeks.","Treated patients showed improvements in forced vital capacity (FVC) and cough severity at all timepoints vs. placebo.","No drug-related serious adverse events or discontinuations reported; most TEAEs mild.","Trial enrolled 10 patients (7 active, 3 placebo); 8 on standard of care (mostly nintedanib).","Biomarkers integrin beta-6 and PRO-C3 reduced in bexotegrast arm vs. placebo at weeks 4 and 12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228712,"accession_number":"0001746473-24-000073","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics Q1 net loss $47.0M; bexotegrast adaptive Phase 2b/3 accelerated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $47.0M in Q1 2024 vs $37.5M in Q1 2023; R&D expenses rose to $37.1M from $29.3M.","BEACON-IPF Phase 2b/3 adaptive design upsized to 360 patients; enrollment completion expected Q1 2025.","Phase 2a PET imaging trial completed; topline data on total lung collagen and FVC expected in weeks.","Oxford loan facility upsized by $50M to $150M; $30M drawn. Cash $483.9M funded through 2026.","Regulatory clearance for PLN-101325 Phase 1 in muscular dystrophy; Phase 1 of PLN-101095 in solid tumors ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247350,"accession_number":"0001193125-24-065416","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Pliant Therapeutics announces accelerated Phase 2b/3 trial for bexotegrast and upsizes debt facility to $150M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BEACON-IPF trial implemented as pivotal, adaptive Phase 2b/3 design after EU and global health authority acceptance; expected to shorten late-stage development.","Phase 3 enrollment begins immediately after Phase 2b completes; sample size increased by 90 patients to support registration.","Oxford Finance debt facility upsized to $150M from $100M; initial $30M drawn, additional $70M contingent on bexotegrast milestones.","Cash and equivalents of $495.7M as of Dec 31, 2023 plus new facility expected to fund operations through 2026.","Bexotegrast is an oral dual-selective αvβ6/αvβ1 integrin inhibitor for IPF and PSC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247349,"accession_number":"0001746473-24-000041","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics reports Q4 2023 net loss of $41.1M; positive bexotegrast data in PSC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.1M vs $35.1M YoY; R&D expenses $33.2M (+32% YoY) driven by bexotegrast costs.","Cash $495.7M; expected to fund operations into H2 2026.","Positive 12-week data from 320 mg cohort of INTEGRIS-PSC: reduced ELF and PRO-C3, improved bile flow.","BEACON-IPF Phase 2b enrolling ~270 patients; 24-week PSC data expected mid-2024.","PLN-101095 Phase 1 solid tumors enrolling third cohort; DMD regulatory filing expected Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":1580000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247348,"accession_number":"0001193125-24-023459","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pliant reports positive Phase 2a data for bexotegrast 320 mg in PSC; fibrosis markers improved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bexotegrast 320 mg well tolerated with no drug-related severe or serious adverse events; 96% of 27 patients completed 12 weeks.","Reduced ELF and PRO-C3 levels relative to placebo at Week 12, indicating antifibrotic activity.","Stabilized alkaline phosphatase and showed improved hepatocyte function and bile flow on contrast MRI vs placebo.","Statistically significant reduction in itch Numerical Rating Scale at Week 12 for the 320 mg dose.","Company plans to share data with regulatory authorities to discuss potential registration path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264806,"accession_number":"0001746473-23-000072","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics reports Q3 net loss of $41.5M; positive bexotegrast PSC interim data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.5M vs $30.6M in prior-year quarter; R&D expense $32.3M, G&A $15.3M.","Cash, cash equivalents and short-term investments of $523.6M, funding operations into H2 2026.","Positive 12-week data from Phase 2a INTEGRIS-PSC trial; 160 mg dose showed statistically significant reduction in ELF and PRO-C3 vs placebo.","DSMB recommended INTEGRIS-PSC continue without modification; 320 mg data expected Q1 2024.","Appointed Minnie Kuo as Chief Development Officer and Mishima Gerhart as Chief Regulatory Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1580000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264805,"accession_number":"0001746473-23-000062","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Pliant Therapeutics signs 7-year lease for 100,904 sq ft in South San Francisco, terminates old lease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leased 100,904 rentable sq ft at 331 Oyster Point Blvd, South San Francisco for 7-year initial term.","Base rent starts at $0.26M/month in year 1 (based on phased rentable sq ft) and rises to $0.71M/month in year 7.","Old lease at 260 Littlefield Ave will terminate 60 days after new lease commencement; no early termination penalties.","Required $1.43M letter of credit; Tenant responsible for operating expenses and has 8-year extension option.","Right of first offer on 33,333 sq ft on 2nd floor, subject to superior right of NGM Biopharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282010,"accession_number":"0001193125-23-241849","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pliant Therapeutics reports positive Phase 2a INTEGRIS-PSC data for bexotegrast in PSC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial met primary safety endpoint; bexotegrast well tolerated with 94% completing 12 weeks, no drug-related SAEs.","Exploratory efficacy: significant reduction in ELF score and PRO-C3 at 160 mg vs placebo at Week 12.","Dose-dependent trend in ALP reduction; MRI imaging suggests improved hepatocyte function and bile flow.","High-dose 320 mg interim data expected Q1 2024; full 24-week data mid-2024.","Company to host webcast today at 8:00 AM ET to discuss results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282009,"accession_number":"0001746473-23-000051","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics reports Q2 loss of $41.2M; initiates Phase 2b IPF trial, expects PSC data Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.2M vs $29.5M prior year; R&D $33.0M, G&A $14.6M.","Cash, equivalents & short-term investments $555.2M; sufficient into H2 2026.","Initiated Phase 2b BEACON-IPF trial of bexotegrast in IPF (~270 patients, 160/320 mg).","INTEGRIS-PSC Phase 2a 12-week interim data from 40/80/160 mg cohorts expected Q3 2023.","Promoted Dr. Scott Turner to Chief Scientific Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":1580000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301063,"accession_number":"0001746473-23-000036","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pliant Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class III director nominees (Coulie, Crowell, Bruhn) elected; Coulie received 48.3M for, 1.1M withhold.","Non-binding say-on-pay proposal approved with 47.99M for, 1.38M against, 36k abstain.","Ratification of Deloitte & Touche LLP as auditor for FY2023 passed with 54.81M for, 12.5k against.","Broker non-votes totaled 5,432,103 shares on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301062,"accession_number":"0001746473-23-000029","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics Q1 net loss $37.5M; cash $577M; positive IPF 24-wk data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $37.5M vs $28.1M YoY; R&D expense $29.3M, G&A $14.2M.","Cash and short-term investments $577.3M, expected to fund operations into H2 2026.","INTEGRIS-IPF 320 mg 24-week data: bexotegrast well-tolerated with durable FVC, QLF, and cough improvements.","Key 2023 milestones: INTEGRIS-PSC 12-wk data Q3; BEACON-IPF Ph2b start mid-2023; Ph1 oncology trial start Q2.","Closed Jan 2023 public offering raising $269.9M net proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":1332000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301061,"accession_number":"0001193125-23-128616","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pliant Therapeutics reports positive Phase 2a data for bexotegrast in IPF; FVC decline reduced 68% vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bexotegrast 320 mg well tolerated up to 40 weeks; no drug-related serious adverse events.","FVC decline reduced 68% vs placebo: mean FVCpp change -0.8% vs -2.5% at Week 24.","89% of patients with FVC increase at Week 12 maintained increase through Week 24.","QLF imaging showed fibrosis stabilization in bexotegrast group vs progression in placebo.","BEACON-IPF Phase 2b trial (160/320 mg, ~270 patients) to initiate in mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320950,"accession_number":"0001746473-23-000007","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant reports Q4 2022 net loss $35.1M; positive bexotegrast data, $287.5M raise extends runway to H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Bexotegrast 320 mg in IPF Phase 2a showed statistically significant FVC increases at 12 weeks; no drug-related severe AEs.","Closed $287.5M equity offering in Jan 2023; net proceeds $269.9M, extending cash runway into second half of 2026.","Q4 2022 net loss $35.1M ($24.5M prior year); R&D expenses $25.1M, G&A $14.3M.","24-week INTEGRIS-IPF 320 mg data expected Q2 2023; Phase 2b IPF trial initiation mid-2023.","EMA granted Orphan Drug designation for bexotegrast in IPF; Novartis terminated PLN-1474 deal and returned rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320949,"accession_number":"0001193125-23-064549","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pliant Therapeutics appoints Thomas McCourt and Darren Cline to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 8 to 10 members; McCourt (Class II) and Cline (Class I) appointed effective March 6, 2023.","Both deemed independent; McCourt joins Compensation Committee, Cline joins Audit Committee.","Each receives annual retainer of $40,000; McCourt $5,000 for Comp Committee, Cline $7,500 for Audit Committee.","Each granted option to purchase 22,000 shares, vesting monthly over three years.","Standard indemnification agreements entered into with both new directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320948,"accession_number":"0001193125-23-046525","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Novartis terminates collaboration with Pliant; discontinues NASH program PLN-1474","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novartis notified Pliant on Feb 17, 2023 of termination of Collaboration and License Agreement, effective April 18, 2023.","Novartis is divesting clinical NASH assets and discontinuing development of PLN-1474 (integrin αvβ1 inhibitor for liver fibrosis).","Pliant had received $50M upfront and $29M in contingent payments; up to $416M in future milestones and royalties now terminated.","All rights and licenses, including PLN-1474 and validated research target compounds, revert to Pliant.","Research term for up to three additional integrin targets concludes Q1 2023; one target validated with multiple development candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320947,"accession_number":"0001193125-23-015276","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Pliant Therapeutics launches $250M equity offering; prelim cash $331.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents and short-term investments of $331.2M as of Dec 31, 2022 (unaudited).","Public offering of 8.33M shares at $30/share; gross proceeds ~$250M (or ~$287.5M if overallotment exercised).","Underwriters: J.P. Morgan and Piper Sandler; offering expected to close Jan 27, 2023.","Company also granted underwriters 30-day option for up to 1.25M additional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320946,"accession_number":"0001193125-23-013173","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pliant Therapeutics launches underwritten public offering; terminates ATM prospectus","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company commenced an underwritten public offering of common stock; terms not disclosed.","No shares were sold under prior $150M ATM facility from July 2021 to January 2023.","Existing Sales Agreement with Cantor Fitzgerald remains in effect but no sales until new prospectus filed.","Offering made via effective shelf registration statement (Form S-3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320945,"accession_number":"0001193125-23-012607","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pliant Therapeutics: Bexotegrast 320 mg shows significant FVC increase in IPF Phase 2a trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["320 mg group met primary/safety endpoints; no drug-related severe/serious adverse events over 12 weeks.","Mean FVC increase of +29.5 mL from baseline vs placebo decline of 110.7 mL (+140 mL vs placebo, p<0.05 at all timepoints).","No bexotegrast-treated patients had FVCpp decline ≥10%; QLF progression slowed vs placebo (0.20% vs 1.46%).","PRO-C3 and integrin beta-6 biomarkers reduced at 4 and 12 weeks (p<0.01 and p<0.0001 vs placebo).","Phase 2b trial planned for mid-2023; final 24-week data from 320 mg cohort expected Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320944,"accession_number":"0001193125-23-004216","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pliant Therapeutics presents at J.P. Morgan Healthcare Conference; no material financial or clinical updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company presented at 41st Annual J.P. Morgan Healthcare Conference on Jan 9, 2023.","Corporate slide deck furnished as Exhibit 99.1, but full content not provided in filing excerpt.","No specific financial, clinical, or pipeline updates included in the available slide title.","Presentation covers 'Developing Novel Treatments for Fibrotic Diseases' — no new data points offered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339062,"accession_number":"0001193125-22-289077","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pliant Therapeutics director Neil Exter retires; board size reduced to eight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil Exter retired from the Board and Compensation Committee effective November 16, 2022.","Retirement not due to any disagreement with the company on operations, policies, or practices.","Board size reduced from nine to eight members, effective November 17, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339061,"accession_number":"0001746473-22-000030","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics Q3 loss $30.6M; positive Phase 2a IPF data; $215M offering closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.6M in Q3 2022 vs $27.0M prior year; cash & investments $360.2M, funding to mid-2025.","Positive Phase 2a data for bexotegrast in IPF: dose-dependent improvement in FVC, QLF, and biomarkers over 12 weeks.","Closed public offering yielding $215.4M net proceeds to fund clinical programs and operations.","Appointed Dr. Katharine Knobil to Board; oncology IND submission expected by end of 2022.","DSMB reviews for INTEGRIS-IPF and INTEGRIS-PSC trials recommended continuation without modification."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":7720000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356435,"accession_number":"0001193125-22-246364","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2022-09-16T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Pliant Therapeutics appoints Katharine Knobil to Board, amends bylaws","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Katharine Knobil appointed to newly created Board seat; term expires at 2025 annual meeting.","Knobil will serve on R&D Committee; qualifies as independent director.","She receives option for 30,000 shares vesting over 3 years, annual retainer $39,000 prorated.","Board approved Second Amended and Restated Bylaws with enhanced shareholder proposal requirements and emergency procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356434,"accession_number":"0001746473-22-000025","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pliant Therapeutics Q2 net loss $29.5M; pro-forma cash $379.8M after $215.7M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.5M in Q2 2022 vs $22.8M in prior-year quarter; R&D expenses $26.3M (up from $19.2M).","Pro-forma cash, cash equivalents and short-term investments of $379.8M as of June 30, 2022.","PLN-74809 INTEGRIS-IPF Phase 2a met primary endpoint; dose-dependent effects on FVC and QLF observed.","FDA Fast Track designation for PLN-74809 in PSC; topline data from INTEGRIS-PSC expected H1 2023.","Received $4.0M milestone from Novartis collaboration; loan facility with Oxford Finance provides up to $100M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":6238000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356433,"accession_number":"0001193125-22-193726","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2022-07-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Pliant Therapeutics raises ~$200M in public offering, reports preliminary cash of $163.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and short-term investments of $163.6M as of June 30, 2022.","Public offering of 10.8M shares at $18.50/share; gross proceeds ~$200M, up to $230M with overallotment.","Underwriters granted 30-day option to purchase up to 1.6M additional shares at same price.","Offering expected to close July 15, 2022.","Underwriting agreement with J.P. Morgan and Cowen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356432,"accession_number":"0001193125-22-190873","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pliant Therapeutics reports positive Phase 2a data for PLN-74809 in IPF; FVC and QLF improved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INTEGRIS-IPF Phase 2a met primary and secondary endpoints; PLN-74809 well tolerated with no drug-related SAEs or discontinuations.","Pooled PLN-74809 showed 80% reduction in FVC decline vs placebo (-15.1 mL vs -74.1 mL); 80 mg dose showed +24.6 mL FVC increase from baseline.","Dose-dependent reduction in ≥10% FVCpp decline: 18.2% (40mg), 8.7% (80mg), 4.5% (160mg) vs 17.4% placebo.","QLF imaging showed dose-dependent antifibrotic effect; 160 mg group showed 0.00% mean change vs 1.15% placebo.","Company to discuss data with regulators; 320 mg cohort data expected early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374858,"accession_number":"0001193125-22-176473","cik":1746473,"company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pliant shareholders re-elect directors, approve say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected John Curnutte (22.7M for) and Smital Shah (22.7M for) as Class II directors.","Advisory vote on named executive officer compensation passed with 27.9M for, 111.6K against.","Advisory vote on frequency of future say-on-pay approved with 28.0M favoring one-year interval.","Ratification of Deloitte & Touche as independent auditor for FY2022 approved with 34.1M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":77400313.50806451,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-17T23:59:59+00:00|374858"}